The Experts below are selected from a list of 5622 Experts worldwide ranked by ideXlab platform
Bradley J. Monk - One of the best experts on this subject based on the ideXlab platform.
-
Interstitial Brachytherapy in the treatment of advanced and recurrent vulvar cancer.
American Journal of Obstetrics and Gynecology, 1999Co-Authors: Krishnansu S. Tewari, Fabio Cappuccini, A.m. Nisar Syed, Ajmel Puthawala, Philip J. Disaia, Michael L. Berman, Alberto Manetta, Bradley J. MonkAbstract:Abstract Objective: Our purpose was to evaluate the role of Interstitial Brachytherapy in vulvar cancer management. Study Design: From 1985-1992 we performed a retrospective study of patients treated at the University of California, Irvine Medical Center, and Long Beach Memorial Medical Center. Results: Eleven patients received Interstitial Brachytherapy, with (n = 5) or without (n = 6) external beam radiotherapy, for locally advanced (n = 5) or recurrent (n = 6) vulvar cancer. Local control was achieved in all patients. Ten patients have died of disease at a mean interval of 33 months from the time of treatment, with 9 patients having maintenance of local control at death. One patient is alive without disease after 77 months of follow-up. There were 2 cases of local necrosis (18%) and 1 case of rectovaginal fistula (9%). Conclusion: Local control of advanced vulvar cancer can be achieved with Interstitial Brachytherapy, with or without external beam radiotherapy. With improved systemic therapy this treatment modality may be used to salvage women with bulky, symptomatic tumors. (Am J Obstet Gynecol 1999;181:91-8.)
Guanghui Cheng - One of the best experts on this subject based on the ideXlab platform.
-
Application of transrectal ultrasound in guiding Interstitial Brachytherapy for advanced cervical cancer.
Journal of contemporary brachytherapy, 2020Co-Authors: Yuanqiang Lin, Guanghui Cheng, Dan Shi, Hui WangAbstract:Purpose To investigate the role of transrectal ultrasound guidance in Interstitial Brachytherapy for cervical cancer. Material and methods Forty-eight patients who underwent Interstitial Brachytherapy treatment for cervical cancer between January 2017 and January 2018 were enrolled in the study. The distances between each inserted needle and the lesion were measured at seven sites by ultrasound (D1-D7) and compared to the corresponding distances (M1-M7) when visualised with nuclear magnetic resonance imaging (MRI). Measurements were paired on the basis of the observation sites, e.g. D1 and M1, D2 and M2. The statistical differences, intraclass correlation coefficients (ICCs), and linear relationships for the paired measurements were calculated. Results No significant differences were found between the paired M and D measurements, with all ICCs showing high levels of concordance (0.81-0.93). Conclusions Transrectal ultrasound showed strong agreement with MRI results in determining the position of the inserted needles. Transrectal ultrasound is a useful tool for guided Interstitial Brachytherapy and is appropriate for widespread use in the treatment of locally advanced cervical cancer.
-
Image-guided Interstitial Brachytherapy boost for nasopharyngeal carcinoma: technical aspects.
Journal of Contemporary Brachytherapy, 2020Co-Authors: Naoya Murakami, Guanghui Cheng, Seiichi Yoshimoto, Jun ItamiAbstract:Nasopharyngeal cancer generally responds well to concurrent chemoradiotherapy (CCRT). However, there is a small group of patients who respond poorly to CCRT, and experience local residual tumor or local relapse. Although several attempts have been performed to such a group of patients including re-irradiation with external beam radiation therapy (EBRT) or salvage surgery, clinical results remain unsatisfactory. Intracavitary Brachytherapy (ICBT) boost after CCRT with EBRT has been explored, however, its efficacy is limited to those with superficial residual tumors. For those residual tumors thickness with more than 5 mm, Interstitial Brachytherapy (ISBT) boost would be an appropriate modality of choice. Here, we describe technical aspects of the high-dose-rate Interstitial Brachytherapy (HDR-ISBT) boost for nasopharyngeal cancer (NPC) patients who responded poorly to the CCRT with EBRT.
-
Image-guided high-dose-rate Interstitial Brachytherapy technique for locally recurrent rectal cancer in perineum.
Journal of Contemporary Brachytherapy, 2018Co-Authors: Yuting Gao, Zhipeng Zhao, Jie Han, Guanghui ChengAbstract:Purpose The aim of the report was the evaluation of application with image-guided high-dose-rate (HDR) Interstitial Brachytherapy in patients undergoing conventional chemo-radiotherapy for perineal locally recurrent rectal cancer (LRRC). Material and methods 75-year-old female patient presented with LRRC three years after total mesorectal excision (TME) surgery for rectal cancer with tubular adenocarcinoma (stage IIIB). Despite conventional chemotherapy and external beam radiotherapy, the re-recurrent lesion expanded as 4.5 × 5.5 cm2 located in perineum with skin invasion. The loco-regional recurrent tumor was treated with HDR Interstitial Brachytherapy under ultrasound guidance and magnetic resonance imaging-based treatment planning. The Brachytherapy dose was 50 Gy in 10 fractions of 5 Gy each for 5 weeks. Results Removal of the perineal LRRC was securely achieved by image-guided HDR Interstitial Brachytherapy technique. The refractory tumor healed uneventfully after Interstitial Brachytherapy without recurrence during 26 months of follow-up. The patient had good quality of life without serious complications of treatment. Conclusions Image-guided HDR Interstitial Brachytherapy in selected patient with LRRC in perineum is a proven, effective, and safe treatment method with relatively long-term outcome.
-
Successful salvage treatment of refractory recurrence of maxillary sinus carcinoma using image-guided high-dose-rate Interstitial Brachytherapy
Journal of Contemporary Brachytherapy, 2018Co-Authors: Yin Zhang, Qianqian Chen, Zhipeng Zhao, Guanghui ChengAbstract:This case report illustrates a treatment effect of image-guided high-dose-rate (HDR) Interstitial Brachytherapy for refractory recurrence of maxillary sinus carcinoma. A 61-year-old male was previously admitted to another hospital and received surgery because of left maxillary sinus squamous cell carcinoma (SCC) 6 years ago. Tumor regrowth was noted 2 years after the initial radical surgery. The patient accepted local excision again for the recurrence, followed by external beam radiotherapy. Despite salvage treatment with surgery and external irradiation, the lesion expanded as 4.8 × 4.4 × 4.0 cm3. Because the patient refused palliative resection, we recommended technique of image-guided HDR Interstitial Brachytherapy. The total doses of 42 Gy in 12 fractions were delivered to the whole recurrent tumor. Removal of the recurrent tumor was securely achieved by HDR Interstitial Brachytherapy, guided with ultrasound. The refractory tumor in the patient healed uneventfully after HDR Interstitial Brachytherapy without recurrence during 8 months of follow-up. This case is remarkable because the patient experienced complete remission by a safe and practicable method with image-guided HDR Interstitial Brachytherapy.
-
Image-guided high-dose-rate Interstitial Brachytherapy – a valuable salvage treatment approach for loco-regional recurrence of papillary thyroid cancer
Journal of contemporary brachytherapy, 2016Co-Authors: Hongfu Zhao, Guanghui Cheng, Dongmei Han, Zhipeng ZhaoAbstract:PURPOSE To report the treatment effect of image-guided high-dose-rate (HDR) Interstitial Brachytherapy for refractory recurrence of papillary thyroid cancer (PTC). CASE REPORT This 66-year-old female presented with recurrence 5 years after thyroidectomy for PTC. Despite external irradiation and radioactive (131)I, the lesion expanded as 3.7 × 3.0 × 2.3 cm(3) and 2.0 × 1.5 × 1.5 cm(3). The locoregional recurrent tumor was treated with image-guided HDR Interstitial Brachytherapy. The total dose of 30 Gy in 6 fractions were delivered on the whole recurrent tumor. RESULTS Removal of the recurrent tumor was securely achieved by HDR Interstitial Brachytherapy guided with ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) scanning. The refractory tumor in the patients healed uneventfully after HDR Interstitial Brachytherapy without recurrence during the 14 months of follow-up. CONCLUSIONS The image-guided HDR Interstitial Brachytherapy may be a valuable salvage treatment approach for refractory recurrence of PTC.
N. Zamboglou - One of the best experts on this subject based on the ideXlab platform.
-
Role of Interstitial Brachytherapy in the treatment of malignant disease.
Oncology Research and Treatment, 2001Co-Authors: C. Kolotas, N. ZamboglouAbstract:Interstitial Brachytherapy was first applied using radium needles, with minimum protection of physicians and nurses. Modern techniques involve the use of radionuclide 192Ir as the source us
-
Navigation system for Interstitial Brachytherapy.
Radiotherapy and Oncology, 2000Co-Authors: Gerd Straßmann, C. Kolotas, Reinhaud Heyd, Stefan Walter, Dimos Baltas, Thomas Martin, Hans Vogt, Georgios Ioannidis, Georgios Sakas, N. ZamboglouAbstract:Abstract Purpose : To develop a computed tomography (CT) based electromagnetic navigation system for Interstitial Brachytherapy. This is especially designed for situations when needles have to be positioned adjacent to or within critical anatomical structures. In such instances interactive 3D visualisation of the needle positions is essential. Methods and materials : The material consisted of a Polhemus electromagnetic 3D digitizer, a Pentium 200 MHz laptop and a voice recognition for continuous speech. In addition, we developed an external reference system constructed of Perspex which could be positioned above the tumour region and attached to the patient using a non-invasive fixation method. A specially designed needle holder and patient bed were also developed. Measurements were made on a series of phantoms in order to study the efficacy and accuracy of the navigation system. Results : The mean navigation accuracy of positioning the 20.0 cm length metallic needles within the phantoms was in the range 2.0–4.1 mm with a maximum of 5.4 mm. This is an improvement on the accuracy of a CT-guided technique which was in the range 6.1–11.3 mm with a maximum of 19.4 mm. The mean reconstruction accuracy of the implant geometry was 3.2 mm within a non-ferromagnetic environment. We found that although the needles were metallic this did not have a significant influence. We also found for our experimental setups that the CT table and operation table non-ferromagnetic parts had no significant influence on the navigation accuracy. Conclusions : This navigation system will be a very useful clinical tool for Interstitial Brachytherapy applications, particularly when critical structures have to be avoided. It also should provide a significant improvement on our existing technique.
Vratislav Strnad - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of oral cavity and oropharyngeal cancer. Indications, technical aspects, and results of Interstitial Brachytherapy.
Strahlentherapie und Onkologie, 2004Co-Authors: Vratislav StrnadAbstract:Excellent local control rates of Interstitial Brachytherapy in oral cavity cancer and oropharyngeal carcinoma have been demonstrated in different retrospective studies. Compared to external-beam radiation therapy the high local control rates with a low rate of side effects obtained by Interstitial Brachytherapy are the result of a steep dose reduction in the implant-surrounding normal tissues. Therefore, Interstitial Brachytherapy offers rather the possibility to give high doses without inevitably leading to high complication rates. Low-dose-rate (LDR) and pulsed-dose-rate (PDR) Interstitial Brachytherapy with 0.4-0.55 Gy/h/24 h for tumors of the oral cavity and oropharynx in selected patients is a proven, effective and safe treatment method with excellent long-term data both as a sole treatment modality and a postoperative method, as well as a unique treatment method of head and neck tumors in previously irradiated areas. This paper deals with the technical aspects of Interstitial Brachytherapy, that seem to be relevant to high-quality outcome, and gives an overview of indications as well as past and recent results of Interstitial Brachytherapy in head and neck cancer.
Jian-guo Zhang - One of the best experts on this subject based on the ideXlab platform.
-
Mandibular growth in survivors of pediatric parotid gland carcinoma treated with Interstitial Brachytherapy
Pediatric Blood & Cancer, 2018Co-Authors: Ming-wei Huang, Lei Zheng, Guo-hao Zhang, Dan Zhao, Jian-guo ZhangAbstract:BACKGROUND The aim of the study was to present long-term results of mandibular growth in pediatric parotid gland carcinoma survivors treated with Interstitial Brachytherapy. PROCEDURE Twenty-five survivors of pediatric parotid gland carcinoma treated with iodine-125 seed Interstitial Brachytherapy were included for quantitative analysis, including three dimensional (3D) cephalometry and measurement of mandibular volume. RESULTS 3D cephalometry showed that the median fore-and-aft increments of the lengths of the condyle, the ramus, and the body of the mandible were 1.23, 0.19, and 1.66 mm for the affected side, respectively, and were 1.37, 1.95, and 3.42 mm for the unaffected side, respectively. The difference in increments of the ramus was statistically significant between the affected side and the unaffected side (P = 0.003; P
-
The role of 125I Interstitial Brachytherapy for inoperable parotid gland carcinoma.
Brachytherapy, 2018Co-Authors: Ming-wei Huang, Jian-guo ZhangAbstract:Abstract Purpose The treatment of inoperable parotid gland carcinoma is challenging and controversial. The purpose of this paper was to present our experience in treating this malignancy using 125I Interstitial Brachytherapy. Methods and Materials Thirteen patients with advanced carcinomas of the parotid gland were included and treated with 125I Interstitial Brachytherapy in Peking University School and Hospital of Stomatology from January 2003 to December 2015. All patients were treated with 125I Interstitial Brachytherapy as a sole modality for the primary tumor. Furthermore, all of them were treated with neck dissection with/without adjunctive external beam radiotherapy for the neck, simultaneously. The prescription dose of Interstitial Brachytherapy was 140–160 Gy. Results Median followup was 56 months (range: 8–105 months). The 2-year and 5-year local control rates were 91.7% and 58.2%, respectively. The 2-year and 5-year overall survival rates were 100% and 61%, respectively. No cervical lymph node metastasis was observed during the followup. No Interstitial Brachytherapy-related severe complications occurred. Facial nerve function was preserved well. Conclusions 125I Interstitial Brachytherapy is a feasible and effective treatment for inoperable parotid gland carcinomas without severe complications. And neck dissection with/without external beam radiotherapy is necessary for patients with cervical metastasis or at high risk of cervical metastasis.
-
Target volume determination of postoperative 125I seeds Interstitial Brachytherapy in parotid gland carcinoma
Chinese journal of radiological medicine and protection, 2011Co-Authors: Lei Zheng, Ming-wei Huang, Jie Zhang, Jian-guo ZhangAbstract:Objective To explore the method of target volume determination of postoperative 125I seeds Interstitial Brachytherapy in parotid gland carcinoma.Methods A total of 31 cases( 14 males and 17 famales) with primary parotid carcinoma who were treated in Peking University Hospital of Stomatology from Oct 2002 to Nov 2006.The patients' average age was 38.2 years.All patients underwent tumor resection and postoperative 125I seeds Interstitial Brachytherapy with 60 Gy matched peripheral dose.The spiral CT was performed for treatment plan and quality verification before and after the Brachytherapy.The bone and muscle landmarks surrounding parotid were selected as reference for target volume determination.D90 of target volume and dose of organs at risk were calculated,while the target volume and D90 of target volume of verification were compared with that of treatment plan through quality verification.Results The target volume or D90 of target volume before and after treatment was not statistically different.D90 of target volume was more than 60 Gy.During 3 -7 years of follow-up,all patients had no recurrence.ConclusionsAccording to the follow-up results,the method used for target volume determination in this paper might be satisfied. Key words: 125 I seeds; Interstitial Brachytherapy; Target volume; Parotid region
-
Radioactivity seeds Interstitial Brachytherapy treating malignant salivary gland tumors
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2011Co-Authors: Jie Zhang, Ming-wei Huang, Lei Zheng, Shu-ming Liu, Ling-fei Jia, Yan Shi, Jian-guo ZhangAbstract:OBJECTIVE To detect the efficacy of (125)I radioactive seeds implanting treating malignant salivary gland tumors. METHODS Forty-three patients with malignant salivary gland tumors of head neck were treated with (125)I radioactivity seeds Interstitial Brachytherapy at Peking University Stomatologic Hospital between 2001 and 2008. These patients were implanted with (125)I radioactivity seeds with the dosage of 120 to 160 Gy. The treatment response, local control rate and survival rate were evaluated and the adverse events observed. RESULTS Twenty-nine patients had complete remission (CR)of their tumors, and seven patients partial remission (PR), The response rate was 83.7%. The patients were followed up for 8 to 48 months (median 21 months). The local control rate was 79%, and total survival rate 76.7%. No serious side radiotherapeutic effect was observed. CONCLUSION Radioactivity seeds Interstitial Brachytherapy is an effective form of treatment for patients with unresectable malignant salivary gland tumors.
-
Influence of 125I seed Interstitial Brachytherapy on recovery of facial nerve function
Chinese journal of radiological medicine and protection, 2010Co-Authors: Tie-li Song, Jie Zhang, Lei Zheng, Zhi-gang Cai, Zhao-hui Yang, Jian-guo ZhangAbstract:Objective To study the influence of 125I seed Interstitial Brachytherapy in parotid region on the recovery of facial nerve function. Methods A total of the data of 21 patients with primary parotid carcinoma were treated with resection and 125I Interstitial Brachytherapy. All the patients had no facial palsy before operation and the prescribed dose was 60 Gy. During 4 years of follow-up, the HouseBrackmann grading scales and ENoG were used to evaluate the function of facial nerve. According to the modified regional House-Brackmann grading scales, the facial nerve branches of patients in affected side were divided into normal and abnormal groups, and were compared with those in contra-lateral side.Results Post-operation facial palsy occurred in all the patients, but the facial palsy recovered within 6 months. The latency time differences between affected side and contralateral side were statistically significant in abnormal group from 1 week to 6 months after treatment ( t = 2.362, P = 0.028 ), and were also different in normal group 1 week after treatment ( t = 2.522, P = 0.027 ). Conclusions 125I Interstitial Brachytherapy has no influence on recovery of facial nerve function after tumor resection and no delayed facial nerve damage. Key words: 125I seed; House-Brackmann grading scales; Electroneurography ( ENoG ); Latency time (LT)
